ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of $4.79 billion. The enterprise value is $5.56 billion.
| Market Cap | 4.79B |
| Enterprise Value | 5.56B |
Important Dates
The last earnings date was Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmunityBio has 691.57 million shares outstanding. The number of shares has increased by 57.06% in one year.
| Shares Outstanding | 691.57M |
| Shares Change (YoY) | +57.06% |
| Shares Change (QoQ) | +32.28% |
| Owned by Insiders (%) | 77.59% |
| Owned by Institutions (%) | 9.81% |
| Float | 160.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16,011.40 |
| Forward PS | 162.43 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18,409.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.64
| Current Ratio | 3.64 |
| Quick Ratio | 3.21 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.39 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -147.60% |
| Return on Capital (ROIC) | -170.57% |
| Revenue Per Employee | $481 |
| Profits Per Employee | -$956,946 |
| Employee Count | 628 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -40,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +150.00% in the last 52 weeks. The beta is -0.23, so ImmunityBio's price volatility has been lower than the market average.
| Beta (1Y) | -0.23 |
| 52-Week Price Change | +150.00% |
| 50-Day Moving Average | 6.35 |
| 200-Day Moving Average | 3.91 |
| Relative Strength Index (RSI) | 47.49 |
| Average Volume (30 Days) | 7,506,282 |
Short Selling Information
The latest short interest is 55.14 million, so 7.97% of the outstanding shares have been sold short.
| Short Interest | 55.14M |
| Short Previous Month | 54.84M |
| Short % of Shares Out | 7.97% |
| Short % of Float | 34.36% |
| Short Ratio (days to cover) | 5.19 |
Income Statement
In the last 12 months, ImmunityBio had revenue of $302,000 and -$600.96 million in losses. Loss per share was -$1.09.
| Revenue | 302,000 |
| Gross Profit | 302,000 |
| Operating Income | -345.87M |
| Pretax Income | -601.00M |
| Net Income | -600.96M |
| EBITDA | -439.89M |
| EBIT | -464.13M |
| Loss Per Share | -$1.09 |
Balance Sheet
The company has $170.50 million in cash and $894.78 million in debt, giving a net cash position of -$724.29 million or -$1.05 per share.
| Cash & Cash Equivalents | 170.50M |
| Total Debt | 894.78M |
| Net Cash | -724.29M |
| Net Cash Per Share | -$1.05 |
| Equity / Book Value | -692.01M |
| Book Value Per Share | -1.00 |
| Working Capital | 141.96M |
Cash Flow
In the last 12 months, operating cash flow was -$389.43 million and capital expenditures -$23.42 million, giving a free cash flow of -$412.85 million.
| Operating Cash Flow | -389.43M |
| Capital Expenditures | -23.42M |
| Free Cash Flow | -412.85M |
| FCF Per Share | -$0.61 |
Margins
Gross margin is 100.00%, with operating and profit margins of -114,525.17% and -198,994.04%.
| Gross Margin | 100.00% |
| Operating Margin | -114,525.17% |
| Pretax Margin | -199,007.28% |
| Profit Margin | -198,994.04% |
| EBITDA Margin | -145,657.62% |
| EBIT Margin | -153,686.42% |
| FCF Margin | -136,703.97% |
Dividends & Yields
ImmunityBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -57.06% |
| Shareholder Yield | -57.06% |
| Earnings Yield | -12.43% |
| FCF Yield | -8.54% |
Analyst Forecast
The average price target for ImmunityBio is $6.00, which is -13.48% lower than the current price. The consensus rating is "Hold".
| Price Target | $6.00 |
| Price Target Difference | -13.48% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmunityBio has an Altman Z-Score of -11.56 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.56 |
| Piotroski F-Score | 2 |